-
1
-
-
63149192143
-
Global and local epidemiology of community-acquired pneumonia: The experience of the CAPNETZ network
-
Welte T, Kohnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ network. Semin Respir Crit Care Med 2009;30:127-35
-
(2009)
Semin Respir Crit Care Med
, vol.30
, pp. 127-135
-
-
Welte, T.1
Kohnlein, T.2
-
2
-
-
82455172268
-
Community acquired pneumonia: An unfinished battle
-
Nair GB, Niederman MS. Community acquired pneumonia: an unfinished battle. Med Clin North Am 2011;95:1143-61
-
(2011)
Med Clin North Am
, vol.95
, pp. 1143-1161
-
-
Nair, G.B.1
Niederman, M.S.2
-
3
-
-
33847155159
-
Infectious diseases society of america/american thoracic society consensus guidelines on the management of community-acquired pneumonia in adults
-
Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72
-
(2007)
Clin Infect Dis
, vol.44
, Issue.SUPPL. 2
-
-
Mandell, L.A.1
Wunderink, R.G.2
Anzueto, A.3
-
4
-
-
82555194473
-
New guidelines for the management of adult lower respiratory tract infections
-
Woodhead M. New guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2011;38(6):1250-1
-
(2011)
Eur Respir J
, vol.38
, Issue.6
, pp. 1250-1251
-
-
Woodhead, M.1
-
5
-
-
84874760594
-
En nombre del Grupo de la Gua Multidisciplinar para el Manejo de la Neumona Adquirida en la Comunidad.
-
e1-223.e19. Spanish
-
Torres A, Barberan J, Falguera M, en nombre del Grupo de la Gua Multidisciplinar para el Manejo de la Neumona Adquirida en la Comunidad. Multidisciplinary guidelines for the management of community-acquired pneumonia. Med Clin (Barc) 2013;140(5):223; e1-223.e19. Spanish
-
(2013)
Med Clin (Barc)
, vol.140
, Issue.5
, pp. 223
-
-
Torres, A.1
Barberan, J.2
Falguera, M.3
-
6
-
-
58849141687
-
Adherence to guidelines' empirical antibiotic recommendations and community-acquired pneumonia outcome
-
Dambrava PG, Torres A, Valles X, et al. Adherence to guidelines' empirical antibiotic recommendations and community-acquired pneumonia outcome. Eur Respir J 2008;32(4):892-901
-
(2008)
Eur Respir J
, vol.32
, Issue.4
, pp. 892-901
-
-
Dambrava, P.G.1
Torres, A.2
Valles, X.3
-
7
-
-
28744442236
-
Community-acquired pneumonia intensive care units (capuci) study investigators antibiotic prescription for community-acquired pneumonia in the intensive care unit: Impact of adherence to infectious diseases society of america guidelines on survival
-
Bod M, Rodrguez A, Sole-Violan J, et al. Community-Acquired Pneumonia Intensive Care Units (CAPUCI) Study Investigators. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious diseases Society of America guidelines on survival. Clin Infect Dis 2005;41(12):1709-16
-
(2005)
Clin Infect Dis
, vol.41
, Issue.12
, pp. 1709-1716
-
-
Bod, M.1
Rodrguez, A.2
Sole-Violan, J.3
-
8
-
-
70349252247
-
Guideline concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: Playing by the rules
-
McCabe C, Kirchner C, Zhang H, et al. Guideline concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. Ann Intern Med 2009;169(16):1525-31
-
(2009)
Ann Intern Med
, vol.169
, Issue.16
, pp. 1525-1531
-
-
McCabe, C.1
Kirchner, C.2
Zhang, H.3
-
9
-
-
77649151752
-
Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit
-
Frei CR, Attridge RT, Mortensen EM, et al. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit. Clin Ther 2010;32:293-9
-
(2010)
Clin Ther
, vol.32
, pp. 293-299
-
-
Frei, C.R.1
Attridge, R.T.2
Mortensen, E.M.3
-
10
-
-
1642286527
-
Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia
-
Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004;164:637-44
-
(2004)
Arch Intern Med
, vol.164
, pp. 637-644
-
-
Houck, P.M.1
Bratzler, D.W.2
Nsa, W.3
-
11
-
-
33746334760
-
Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia
-
Waterer GW, Kessler LA, Wunderink RG. Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. Chest 2006;130(1):11-15
-
(2006)
Chest
, vol.130
, Issue.1
, pp. 11-15
-
-
Waterer, G.W.1
Kessler, L.A.2
Wunderink, R.G.3
-
12
-
-
23744472099
-
Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: A prospective randomized study
-
van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomized study. Thorax. 2005; 60(8):672-8.
-
(2005)
Thorax
, vol.60
, Issue.8
, pp. 672-672
-
-
Van Der Eerden, M.M.1
Vlaspolder, F.2
De Graaff, C.S.3
-
13
-
-
84862499347
-
Community acquired pneumonia guidelines: A global perspective
-
Niederman M, Luna C. Community acquired pneumonia guidelines: a global perspective. Semin Respir Crit Care Med 2012;33:298-310
-
(2012)
Semin Respir Crit Care Med
, vol.33
, pp. 298-310
-
-
Niederman, M.1
Luna, C.2
-
14
-
-
34249304464
-
Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock
-
Rodrguez A, Mendia A, Sirvent JM, CAPUCI Study Group. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007;35(6):1493-8
-
(2007)
Crit Care Med
, vol.35
, Issue.6
, pp. 1493-1498
-
-
Rodrguez, A.1
Mendia, A.2
Sirvent, J.M.3
-
15
-
-
63249091069
-
The science of selecting antimicrobials for community -acquired pneumonia (CAP)
-
File T. The science of selecting antimicrobials for community -acquired pneumonia (CAP). J Manag Care Pharm 2009;15(2 Suppl):S5-11
-
(2009)
J Manag Care Pharm
, vol.15
, Issue.2 SUPPL.
-
-
File, T.1
-
16
-
-
33745832293
-
Antibiotic dosage regimens in respiratory tract infections in the pharmacokinetic/pharmacodynamic era
-
9
-
Soy D, Badia JR, Torres A. Antibiotic dosage regimens in respiratory tract infections in the pharmacokinetic/pharmacodynamic era. Curr Respir Med Rev 2006;2(1):89-97; 9
-
(2006)
Curr Respir Med Rev
, vol.2
, Issue.1
, pp. 89-97
-
-
Soy, D.1
Badia, J.R.2
Torres, A.3
-
17
-
-
45949106769
-
Pharmacodynamic optimization of b-lactams in the patient care setting
-
Nicolau DP. Pharmacodynamic optimization of b-lactams in the patient care setting. Crit Care 2008;12:S2
-
(2008)
Crit Care
, vol.12
-
-
Nicolau, D.P.1
-
18
-
-
0141676184
-
High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm
-
Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003;37(6):752-60
-
(2003)
Clin Infect Dis
, vol.37
, Issue.6
, pp. 752-760
-
-
Dunbar, L.M.1
Wunderink, R.G.2
Habib, M.P.3
-
19
-
-
33750849023
-
Levofloxacin 750-mg for 5 days for the treatment of hospitalized fine risk class III/IV community-acquired pneumonia patients
-
Shorr AF, Khashab MM, Xiang JX, et al. Levofloxacin 750-mg for 5 days for the treatment of hospitalized fine risk class III/IV community-acquired pneumonia patients. Respir Med 2006;100(12):2129-36
-
(2006)
Respir Med
, vol.100
, Issue.12
, pp. 2129-2136
-
-
Shorr, A.F.1
Khashab, M.M.2
Xiang, J.X.3
-
20
-
-
34548355192
-
Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data
-
Burgess DS, Hall RG II. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data. Clin Ther 2007;29(7):1421-7
-
(2007)
Clin Ther
, vol.29
, Issue.7
, pp. 1421-1427
-
-
Burgess, D.S.1
Hall, R.G.I.I.2
-
21
-
-
0030802009
-
Intermittent bolus dosing of ceftazidime in critically ill patients
-
Young RJ, Lipman J, Gin T, et al. Intermittent bolus dosing of ceftazidime in critically ill patients. J Antimicrob Chemother 1997;40:269-73
-
(1997)
J Antimicrob Chemother
, vol.40
, pp. 269-273
-
-
Young, R.J.1
Lipman, J.2
Gin, T.3
-
22
-
-
0031772904
-
Continuous vs intermittent infusion of cefuroxime for the treatment of community-acquired pneumonia
-
Ambrose PG, Quindliani R, Nightingale CH, Nicolau DP. Continuous vs. intermittent infusion of cefuroxime for the treatment of community-acquired pneumonia. Infect Dis Clin Pract 1998;7:463-70
-
(1998)
Infect Dis Clin Pract
, vol.7
, pp. 463-470
-
-
Ambrose, P.G.1
Quindliani, R.2
Nightingale, C.H.3
Nicolau, D.P.4
-
23
-
-
80052672933
-
Antibiotics in critically ill patients: A systematic review of the pharmacokinetics of b-lactams
-
Review
-
Goncalves-Pereira J, Povoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of b-lactams. Crit Care 2011;15(5):13; Review
-
(2011)
Crit Care
, vol.15
, Issue.5
, pp. 13
-
-
Goncalves-Pereira, J.1
Povoa, P.2
-
24
-
-
66449092115
-
A systematic review on clinical benefits of continuous administration of b-lactam antibiotics
-
Roberts JA, Webb S, Paterson D, et al. A systematic review on clinical benefits of continuous administration of b-lactam antibiotics. Crit Care Med 2009;37:2071-8
-
(2009)
Crit Care Med
, vol.37
, pp. 2071-2078
-
-
Roberts, J.A.1
Webb, S.2
Paterson, D.3
-
25
-
-
23944504296
-
Continuous versus intermittent intravenous administration of antibiotics: A meta-analysis of randomized controlled trials
-
Kasiakou SK, Sermaides GJ, Michalopoulos A, et al. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomized controlled trials. Lancet Infect Dis 2005;5:581-9
-
(2005)
Lancet Infect Dis
, vol.5
, pp. 581-589
-
-
Kasiakou, S.K.1
Sermaides, G.J.2
Michalopoulos, A.3
-
26
-
-
84855410035
-
Initial management of pneumonia and sepsis: Factors associated with improved outcome
-
Menendez R, Torres A, Reyes S, et al. Initial management of pneumonia and sepsis: factors associated with improved outcome. Eur Respir J 2012;39(1):156-62
-
(2012)
Eur Respir J
, vol.39
, Issue.1
, pp. 156-162
-
-
Menendez, R.1
Torres, A.2
Reyes, S.3
-
27
-
-
77957754399
-
Sociedad Espanola de Neumologa y Ciruga Toracica.Community acquired pneumonia New guidelines of the Spanish Society of Chest Diseases and Thoracic Surgery (SEPAR)]
-
Menendez R, Torres A, Aspa J, et al. Sociedad Espanola de Neumologa y Ciruga Toracica.Community acquired pneumonia. New guidelines of the Spanish Society of Chest Diseases and Thoracic Surgery (SEPAR)]. Arch Bronconeumol 2010;46(10):543-58
-
(2010)
Arch Bronconeumol
, vol.46
, Issue.10
, pp. 543-558
-
-
Menendez, R.1
Torres, A.2
Aspa, J.3
-
28
-
-
84877920559
-
Determining the duration of therapy for patients with community-acquired pneumonia
-
Scalera NM, File TM Jr. Determining the duration of therapy for patients with community-acquired pneumonia. Curr Infect Dis Rep 2013;15(2):191-5
-
(2013)
Curr Infect Dis Rep
, vol.15
, Issue.2
, pp. 191-195
-
-
Scalera, N.M.1
File Jr., T.M.2
-
29
-
-
33745471090
-
Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: A randomized trial
-
Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006;174:84-93
-
(2006)
Am J Respir Crit Care Med
, vol.174
, pp. 84-93
-
-
Christ-Crain, M.1
Stolz, D.2
Bingisser, R.3
-
30
-
-
70149088214
-
Effect of procalcitonin based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: The prohosp randomized controlled trial
-
Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin based guidelines vs. standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009;302:1059-66
-
(2009)
JAMA
, vol.302
, pp. 1059-1066
-
-
Schuetz, P.1
Christ-Crain, M.2
Thomann, R.3
-
31
-
-
36749072042
-
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study
-
Critchley IA, Brown SD, Traczewski MM, et al. National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. Antimicrob Agents Chemother 2007;51(12):4382-9
-
(2007)
Antimicrob Agents Chemother
, vol.51
, Issue.12
, pp. 4382-4389
-
-
Critchley, I.A.1
Brown, S.D.2
Traczewski, M.M.3
-
32
-
-
84892674223
-
-
Available from: http://www.earss.rivm.nl
-
-
-
-
33
-
-
30144441160
-
Penicillins for treatment of pneumococcal pneumonia: Does in vitro resistance really matter?
-
Peterson LR. Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter? Clin Infect Dis 2006;42:224-33
-
(2006)
Clin Infect Dis
, vol.42
, pp. 224-233
-
-
Peterson, L.R.1
-
34
-
-
34547516914
-
Penicillin resistance not a factor in outcome from invasive streptococcus pneumoniae community-acquired pneumonia in adults when appropriate empiric therapy is started
-
Mufson MA, Chan G, Stanek RJ. Penicillin resistance not a factor in outcome from invasive Streptococcus pneumoniae community-acquired pneumonia in adults when appropriate empiric therapy is started. Am J Med Sci 2007;333:161-7
-
(2007)
Am J Med Sci
, vol.333
, pp. 161-167
-
-
Mufson, M.A.1
Chan, G.2
Stanek, R.J.3
-
35
-
-
36048991271
-
The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults
-
File TM Jr. The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults. Int J Antimicrob Agents 2007;30(Suppl 2):S131-4
-
(2007)
Int J Antimicrob Agents
, vol.30
, Issue.SUPPL. 2
-
-
File Jr., T.M.1
-
36
-
-
33746608911
-
Macrolide resistance in bacteremic pneumococcal disease: Implications for patient management
-
Daneman N, McGeer A, Green K, Low DE. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis 2006;43(4):432-8
-
(2006)
Clin Infect Dis
, vol.43
, Issue.4
, pp. 432-438
-
-
Daneman, N.1
McGeer, A.2
Green, K.3
Low, D.E.4
-
37
-
-
78649873377
-
Integrated analysis of focus 1 and focus 2: Randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia
-
ceftaroline group were numerically higher than those for the ceftriaxone group, well tolerated and with a safety profile similar to that of ceftriaxone
-
File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010;51(12):1395-405 ceftaroline group were numerically higher than those for the ceftriaxone group, well tolerated and with a safety profile similar to that of ceftriaxone.
-
(2010)
Clin Infect Dis
, vol.51
, Issue.12
, pp. 1395-1405
-
-
File Jr., T.M.1
Low, D.E.2
Eckburg, P.B.3
-
39
-
-
14644394235
-
Effectiveness of b-lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: Meta-analysis
-
Mills GD, Oehley MR, Arrol B. Effectiveness of b-lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 2005;330:456-60
-
(2005)
BMJ
, vol.330
, pp. 456-460
-
-
Mills, G.D.1
Oehley, M.R.2
Arrol, B.3
-
40
-
-
47049124628
-
Antibacterial class is not obviously important in outpatient pneumonia: A meta-analysis
-
Maimon N, Nopmaneejumruslers C, Marras TK. Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis. Eur Respir J 2008;31(5):1068-76
-
(2008)
Eur Respir J
, vol.31
, Issue.5
, pp. 1068-1076
-
-
Maimon, N.1
Nopmaneejumruslers, C.2
Marras, T.K.3
-
41
-
-
14844300669
-
Immunomodulatory effects of macrolides: Implications for practicing clinicians
-
Siddiqui J. Immunomodulatory effects of macrolides: implications for practicing clinicians. Am J Med 2004;117:26S-9S
-
(2004)
Am J Med
, vol.117
-
-
Siddiqui, J.1
-
43
-
-
35448968988
-
Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro
-
Anderson R, Steel HC, Cockeran R, et al. Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro. J Antimicrob Chemother 2007;60:1155-8
-
(2007)
J Antimicrob Chemother
, vol.60
, pp. 1155-1158
-
-
Anderson, R.1
Steel, H.C.2
Cockeran, R.3
-
44
-
-
58849166805
-
Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia
-
Restrepo MI, Mortensen EM, Waterer GW, et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009;33:153-9
-
(2009)
Eur Respir J
, vol.33
, pp. 153-159
-
-
Restrepo, M.I.1
Mortensen, E.M.2
Waterer, G.W.3
-
45
-
-
77951209165
-
Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia
-
Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010;36:610-20
-
(2010)
Intensive Care Med
, vol.36
, pp. 610-620
-
-
Martin-Loeches, I.1
Lisboa, T.2
Rodriguez, A.3
-
46
-
-
33847173420
-
Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones
-
Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. Chest 2007;131:466-73
-
(2007)
Chest
, vol.131
, pp. 466-473
-
-
Metersky, M.L.1
Ma, A.2
Houck, P.M.3
Bratzler, D.W.4
-
47
-
-
76549123321
-
Prospective, randomized study to compare empirical treatment versus targeted treatment on the basis of the urine antigen results in hospitalized patients with community-acquired pneumonia
-
Falguera M, Ruiz-Gonzalez A, Schoenenberger JA, et al. Prospective, randomized study to compare empirical treatment versus targeted treatment on the basis of the urine antigen results in hospitalized patients with community-acquired pneumonia. Thorax 2010;65:101-6
-
(2010)
Thorax
, vol.65
, pp. 101-106
-
-
Falguera, M.1
Ruiz-Gonzalez, A.2
Schoenenberger, J.A.3
-
48
-
-
79954578994
-
Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: Results from an international surveillance study
-
Jones RN, Farrell DJ, Mendes RE, Sader HS. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. J Antimicrob Chemother 2011;66(Suppl 3):iii69-80
-
(2011)
J Antimicrob Chemother
, vol.66
, Issue.SUPPL. 3
-
-
Jones, R.N.1
Farrell, D.J.2
Mendes, R.E.3
Sader, H.S.4
-
49
-
-
84892677278
-
-
Available from: http://www.fda.gov/newsevents/newsroom/ pressannouncements/ucm231594.htm
-
-
-
-
50
-
-
50149119679
-
In vitro activity of tigecycline and occurrence of tetracycline resistance determinants in isolates from patients enrolled in phase 3 clinical trials for community-acquired pneumonia
-
Bradford PA, Petersen PJ, Tuckman M, Jones CH. In vitro activity of tigecycline and occurrence of tetracycline resistance determinants in isolates from patients enrolled in phase 3 clinical trials for community-acquired pneumonia. Clin Microbiol Infect 2008;14:882-6
-
(2008)
Clin Microbiol Infect
, vol.14
, pp. 882-886
-
-
Bradford, P.A.1
Petersen, P.J.2
Tuckman, M.3
Jones, C.H.4
-
51
-
-
57749206651
-
Tigecycline: In community-acquired pneumonia
-
McKeage K, Keating GM. Tigecycline: in community-acquired pneumonia. Drugs 2008;68:2633-44
-
(2008)
Drugs
, vol.68
, pp. 2633-2644
-
-
McKeage, K.1
Keating, G.M.2
-
52
-
-
57549104883
-
308 Study Group Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: Results from a double-blind randomized phase 3 comparison study with levofloxacin
-
Bergallo C, Jasovich A, Teglia O, et al. 308 Study Group. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 2009;63(1):52-61
-
(2009)
Diagn Microbiol Infect Dis
, vol.63
, Issue.1
, pp. 52-61
-
-
Bergallo, C.1
Jasovich, A.2
Teglia, O.3
-
53
-
-
70449359990
-
313 Study Group Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia
-
Tanaseanu C, Milutinovic S, Calistru PI, et al. 313 Study Group. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm Med 2009;9:44
-
(2009)
BMC Pulm Med
, vol.9
, pp. 44
-
-
Tanaseanu, C.1
Milutinovic, S.2
Calistru, P.I.3
-
54
-
-
84892678500
-
-
Available from: http://www.fda.gov/Drugs/DrugSafety/ucm224370.ht
-
-
-
-
55
-
-
84863373784
-
Cethromycin versus clarithromycin for community-acquired pneumonia: Comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies
-
English ML, Fredericks CE, Milanesio NA, et al. Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies. Antimicrob Agents Chemother 2012;56(4):2037-47
-
(2012)
Antimicrob Agents Chemother
, vol.56
, Issue.4
, pp. 2037-2047
-
-
English, M.L.1
Fredericks, C.E.2
Milanesio, N.A.3
-
56
-
-
84875413952
-
A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-kB inhibition
-
Kobayashi Y, Wada H, Rossios C, et al. A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-kB inhibition. J Pharmacol Exp Ther 2013;345(1):76-84
-
(2013)
J Pharmacol Exp Ther
, vol.345
, Issue.1
, pp. 76-84
-
-
Kobayashi, Y.1
Wada, H.2
Rossios, C.3
-
57
-
-
84892680261
-
-
Available from: http://www.prnewswire. com/news-releases/cempra-inc- announcesinitiation-of-oral-solithromycin-globalphase-3-clinical-trial-in- patients-withcommunity-acquired-bacterialpneumonia-184082501.html
-
-
-
-
58
-
-
77953312824
-
Resistant pathogens in nonnosocomial pneumonia and respiratory failure: Is it time to refine the definition of health-care-associated pneumonia?
-
Schreiber MP, Chan CM, Shorr AF. Resistant pathogens in nonnosocomial pneumonia and respiratory failure: is it time to refine the definition of health-care-associated pneumonia? Chest 2010;137:1283-8
-
(2010)
Chest
, vol.137
, pp. 1283-1288
-
-
Schreiber, M.P.1
Chan, C.M.2
Shorr, A.F.3
-
59
-
-
34948846090
-
Health care-associated pneumonia and community-acquired pneumonia: A single-center experience
-
Micek ST, Kollef KE, Reichley RM, et al. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother 2007;51:3568-73
-
(2007)
Antimicrob Agents Chemother
, vol.51
, pp. 3568-3573
-
-
Micek, S.T.1
Kollef, K.E.2
Reichley, R.M.3
-
60
-
-
44149101259
-
Pneumonia caused by methicillin-resistant Staphylococcus aureus
-
Review
-
Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46(Suppl 5):S378-85; Review
-
(2008)
Clin Infect Dis
, vol.46
, Issue.SUPPL. 5
-
-
Rubinstein, E.1
Kollef, M.H.2
Nathwani, D.3
-
61
-
-
79959711666
-
Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: A uk cohort study
-
e13
-
Chalmers JD, Taylor JK, Singanayagam A, et al. Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study. Clin Infect Dis 2011;53:107; e13
-
(2011)
Clin Infect Dis
, vol.53
, pp. 107
-
-
Chalmers, J.D.1
Taylor, J.K.2
Singanayagam, A.3
-
62
-
-
80053526515
-
Low incidence of multidrug resistant organisms in patients with healthcare-associated pneumonia requiring hospitalization
-
Garcia-Vidal C, Viasus D, Roset A, et al. Low incidence of multidrug resistant organisms in patients with healthcare-associated pneumonia requiring hospitalization. Clin Microbiol Infect 2011;17:1659-65
-
(2011)
Clin Microbiol Infect
, vol.17
, pp. 1659-1665
-
-
Garcia-Vidal, C.1
Viasus, D.2
Roset, A.3
-
63
-
-
80053513739
-
Guideline-concordant therapy and outcomes in healthcare-associated pneumonia
-
Attridge RT, Frei CR, Restrepo MI, et al. Guideline-concordant therapy and outcomes in healthcare-associated pneumonia. Eur Respir J 2011;38:878-87
-
(2011)
Eur Respir J
, vol.38
, pp. 878-887
-
-
Attridge, R.T.1
Frei, C.R.2
Restrepo, M.I.3
-
64
-
-
79958810134
-
Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia
-
Grenier C, Pepin J, Nault V, et al. Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia. J Antimicrob Chemother 2011;66:1617-24
-
(2011)
J Antimicrob Chemother
, vol.66
, pp. 1617-1624
-
-
Grenier, C.1
Pepin, J.2
Nault, V.3
-
65
-
-
84864617002
-
Adding fuel to the flames? It is time to leave HCAP
-
Ewig S, Welte T. Adding fuel to the flames? It is time to leave HCAP. Respir Med 2012;106(9):1309-10
-
(2012)
Respir Med
, vol.106
, Issue.9
, pp. 1309-1310
-
-
Ewig, S.1
Welte, T.2
-
66
-
-
84555209205
-
Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department
-
Shorr AF, Zilberberg MD, Reichley R, et al. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis 2012;54(2):193-8
-
(2012)
Clin Infect Dis
, vol.54
, Issue.2
, pp. 193-198
-
-
Shorr, A.F.1
Zilberberg, M.D.2
Reichley, R.3
-
67
-
-
84860236414
-
Pneumonia in the community caused by multidrug-resistant organisms: Keep working on probabilistic scores
-
Aliberti S, Zanaboni AM, Blasi F. Pneumonia in the community caused by multidrug-resistant organisms: keep working on probabilistic scores. Clin Infect Dis 2012;54(10):1519-20
-
(2012)
Clin Infect Dis
, vol.54
, Issue.10
, pp. 1519-1520
-
-
Aliberti, S.1
Zanaboni, A.M.2
Blasi, F.3
-
68
-
-
26844433194
-
Antiinflammatory action of glucocorticoids-new mechanisms for old drugs
-
Review
-
Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005;353(16):1711-23; Review
-
(2005)
N Engl J Med
, vol.353
, Issue.16
, pp. 1711-1723
-
-
Rhen, T.1
Cidlowski, J.A.2
-
69
-
-
0025153147
-
A controlled trial of early adjunctive treatment with corticosteroids for pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome
-
Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 1990;323(21):1451-7
-
(1990)
California Collaborative Treatment Group. N Engl J Med
, vol.323
, Issue.21
, pp. 1451-1457
-
-
Bozzette, S.A.1
Sattler, F.R.2
Chiu, J.3
-
70
-
-
19944430688
-
Hydrocortisone infusion for severe community-acquired pneumonia: A preliminary randomized study
-
Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005;171:242-8
-
(2005)
Am J Respir Crit Care Med
, vol.171
, pp. 242-248
-
-
Confalonieri, M.1
Urbino, R.2
Potena, A.3
-
71
-
-
84868148522
-
Corticosteroids and ICU course of community acquired pneumonia in Egyptian settings
-
Sabry NA, Omar EE-D. Corticosteroids and ICU course of community acquired pneumonia in Egyptian settings. Pharmacol Pharm 2011;2:73-81
-
(2011)
Pharmacol Pharm
, vol.2
, pp. 73-81
-
-
Sabry, N.A.1
Omar, E.E.-D.2
-
72
-
-
79952561515
-
Effect of corticosteroids on the clinical course of community-acquired pneumonia: A randomized controlled trial
-
Fernandez-Serrano S, Dorca J, Garcia-Vidal C, et al. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care 2011;15:R96
-
(2011)
Crit Care
, vol.15 R
, pp. 96
-
-
Fernandez-Serrano, S.1
Dorca, J.2
Garcia-Vidal, C.3
-
73
-
-
77952307234
-
Efficacy of corticosteroids in community-acquired pneumonia: A randomized double-blinded clinical trial
-
Snijders D, Daniels JM, de Graaff CS, et al. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med 2010;181:975-82
-
(2010)
Am J Respir Crit Care Med
, vol.181
, pp. 975-982
-
-
Snijders, D.1
Daniels, J.M.2
De Graaff, C.S.3
-
74
-
-
79958771376
-
Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: A randomized, double-blind, placebo-controlled trial
-
Meijvis SC, Hardeman H, Remmelts HH, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomized, double-blind, placebo-controlled trial. Lancet 2011;377:2023-30
-
(2011)
Lancet
, vol.377
, pp. 2023-2030
-
-
Meijvis, S.C.1
Hardeman, H.2
Remmelts, H.H.3
-
75
-
-
34548569037
-
Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization
-
Mikami K, Suzuki M, Kitagawa H, et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung 2007;185:249-55
-
(2007)
Lung
, vol.185
, pp. 249-255
-
-
Mikami, K.1
Suzuki, M.2
Kitagawa, H.3
-
76
-
-
84872896068
-
Systemic corticosteroids for community-acquired pneumonia: Reasons for use and lack of benefit on outcome
-
Polverino E, Cilloniz C, Dambrava P, et al. Systemic corticosteroids for community-acquired pneumonia: reasons for use and lack of benefit on outcome. Respirology 2013;18(2):263-71
-
(2013)
Respirology
, vol.18
, Issue.2
, pp. 263-271
-
-
Polverino, E.1
Cilloniz, C.2
Dambrava, P.3
-
77
-
-
84868087224
-
Corticosteroids in the treatment of community-acquired pneumonia in adults: A meta-analysis
-
Nie W, Zhang Y, Cheng J, Xiu Q. Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis. PLoS One 2012;7(10):e47926
-
(2012)
PLoS One
, vol.7
, Issue.10
-
-
Nie, W.1
Zhang, Y.2
Cheng, J.3
Xiu, Q.4
-
78
-
-
84877920907
-
Is prolonged low-dose glucocorticoid treatment beneficial in community-acquired pneumonia?
-
Confalonieri M, Annane D, Antonaglia C, et al. Is prolonged low-dose glucocorticoid treatment beneficial in community-acquired pneumonia? Curr Infect Dis Rep 2013;15(2):158-66
-
(2013)
Curr Infect Dis Rep
, vol.15
, Issue.2
, pp. 158-166
-
-
Confalonieri, M.1
Annane, D.2
Antonaglia, C.3
-
79
-
-
37549020378
-
Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2008
-
Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327
-
(2008)
Crit Care Med
, vol.36
, pp. 296-327
-
-
Dellinger, R.P.1
Levy, M.M.2
Carlet, J.M.3
-
80
-
-
84892676597
-
-
Available from: http://clinicaltrials.gov/ct2/show/NCT00973154
-
-
-
-
81
-
-
37549040562
-
Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats
-
Choi G, Hofstra JJ, Roelofs JJ, et al. Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats. Crit Care Med 2008;36(1):204-10
-
(2008)
Crit Care Med
, vol.36
, Issue.1
, pp. 204-210
-
-
Choi, G.1
Hofstra, J.J.2
Roelofs, J.J.3
-
82
-
-
67650470156
-
Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study)
-
Jaimes F, De La Rosa G, Morales C, et al. Unfractioned heparin for treatment of sepsis: a randomized clinical trial (The HETRASE Study). Crit Care Med 2009;37(4):1185-96
-
(2009)
Crit Care Med
, vol.37
, Issue.4
, pp. 1185-1196
-
-
Jaimes, F.1
De La Rosa, G.2
Morales, C.3
-
83
-
-
46049090201
-
Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th edition)
-
Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: american College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):381S-453S
-
(2008)
Chest
, vol.133
, Issue.6 SUPPL.
-
-
Geerts, W.H.1
Bergqvist, D.2
Pineo, G.F.3
-
84
-
-
0032698105
-
Acute respiratory failure in patients with severe community-acquired pneumonia A prospective randomized evaluation of noninvasive ventilation
-
Confalonieri M, Potena A, Carbone G, et al. Acute respiratory failure in patients with severe community-acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation. Am J Respir Crit Care Med 1999;160(5 Pt 1):1585-91
-
(1999)
Am J Respir Crit Care Med
, vol.160 PART 1
, Issue.5
, pp. 1585-1591
-
-
Confalonieri, M.1
Potena, A.2
Carbone, G.3
-
85
-
-
0347362531
-
Noninvasive ventilation in severe hypoxemic respiratory failure: A randomized clinical trial
-
Ferrer M, Esquinas A, Leon M, et al. Noninvasive ventilation in severe hypoxemic respiratory failure: a randomized clinical trial. Am J Respir Crit Care Med 2003;168:1438-44
-
(2003)
Am J Respir Crit Care Med
, vol.168
, pp. 1438-1444
-
-
Ferrer, M.1
Esquinas, A.2
Leon, M.3
-
86
-
-
0034533147
-
Statins as a newly recognized type of immunomodulator
-
Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6(12):1399-402
-
(2000)
Nat Med
, vol.6
, Issue.12
, pp. 1399-1402
-
-
Kwak, B.1
Mulhaupt, F.2
Myit, S.3
Mach, F.4
-
87
-
-
20244378532
-
Simvastatin blunts endotoxin-induced tissue factor in vivo
-
Steiner S, Speid WS, Pleiner J, et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 2005;111(14):1841-6
-
(2005)
Circulation
, vol.111
, Issue.14
, pp. 1841-1846
-
-
Steiner, S.1
Speid, W.S.2
Pleiner, J.3
-
88
-
-
54349122201
-
Prior statin use is associated with improved outcomes in community-acquired pneumonia
-
e1
-
Chalmers JD, Singanayagam A, Murray MP, Hill AT. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 2008;121(11):1002-7; e1
-
(2008)
Am J Med
, vol.121
, Issue.11
, pp. 1002-1007
-
-
Chalmers, J.D.1
Singanayagam, A.2
Murray, M.P.3
Hill, A.T.4
-
89
-
-
79961024148
-
Understanding the potential role of statins in pneumonia and sepsis
-
Yende S, Milbrandt EB, Kellum JA, et al. Understanding the potential role of statins in pneumonia and sepsis. Crit Care Med 2011;39(8):1871-8
-
(2011)
Crit Care Med
, vol.39
, Issue.8
, pp. 1871-1878
-
-
Yende, S.1
Milbrandt, E.B.2
Kellum, J.A.3
-
90
-
-
79953905093
-
Effect of statin treatment on short term mortality after pneumonia episode: Cohort study
-
Douglas I, Evans S, Smeeth L. Effect of statin treatment on short term mortality after pneumonia episode: cohort study. BMJ 2011;342:d1642
-
(2011)
BMJ
, vol.342
-
-
Douglas, I.1
Evans, S.2
Smeeth, L.3
-
91
-
-
46349099104
-
Acute myocardial infarction in hospitalized patients with community-acquired pneumonia
-
Ramirez J, Aliberti S, Mirsaeidi M, et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. J Clin Infect Dis 2008;47(2):182-7
-
(2008)
J Clin Infect Dis
, vol.47
, Issue.2
, pp. 182-187
-
-
Ramirez, J.1
Aliberti, S.2
Mirsaeidi, M.3
-
92
-
-
84872253001
-
The role of statins in prevention and treatment of community acquired pneumonia: A systematic review and meta-analysis
-
Khan AR, Riaz M, Bin Abdulhak AA, et al. The role of statins in prevention and treatment of community acquired pneumonia: a systematic review and meta-analysis. PLoS One 2013;8(1):e52929
-
(2013)
PLoS One
, vol.8
, Issue.1
-
-
Khan, A.R.1
Riaz, M.2
Bin Abdulhak, A.A.3
|